Is a privately held biopharmaceutical company devoted to the development and commercialization of novel proprietary therapeutic and prophylactic cancer vaccines.
The global cancer immunotherapy market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during the period, 2018-2025 .
The lead candidate FMPV-1 is a neoantigen peptide vaccine which will enter clinical phase in the fourth quarter of 2021. The target is frameshift mutations greatly associated with colorectal cancer including hereditary disease and gastric cancer.
Hollingsworth, R. E. & Jansen, K. NPJ vaccines 4, 7, doi:10.1038/s41541-019-0103-y (2019).
The Company has a highly experienced international management and operational team, an extensive network of industrial and academic partners to optimise and leverage the development of its novel technology.
The CEO Jon Amund Eriksen has established multiple successful cancer immunology companies and is a highly respected individual in the field of peptide vaccines.
Chairman of the Board is Øyvind Kongstun Arnesen. Mr. Kongstun Arnesen has an extensive track record of commercializing cancer research, last as CEO for Ultimovacs ASA and advisor to Radforsk.